Mice bearing IFNGR1KO melanoma tumors do not respond to anti-CTLA-4 therapy, indicating that impairment of the IFN-γ signaling pathway is associated with primary resistance to CTLA-4 inhibition [8]. This evidence concerns the gene CTLA4 and melanoma.